Activating mutations in the SET domain of EZH2 (KMT6A) are seen in some lymphomas (see Table 1) and levels of EZH2 are increased in many carcinomas, including breast and prostate, and in multiple myeloma, where high expression is associated with poor prognosis [38,39,40]. The gene discussed is EZH2; the disease is carcinoma.